We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 161.72 | 18 | 10:52:33 |
From May 2019 to May 2024
By Josh Beckerman
AbbVie Inc. (ABBV) said the U.S. Food and Drug Administration has approved Rinvoq, or upadacitinib, a treatment for rheumatoid arthritis.
The drug is expected to be available in the U.S. later this month.
In February, AbbVie said the FDA granted priority review to its new drug application.
The drug, an oral Janus kinase inhibitor, was approved for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 16, 2019 14:01 ET (18:01 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
